BlockchainFX presale hits $6.28M with 35% bonus tokens, daily USDT rewards, and 90% APY, while Aave Horizon bridges DeFi to real-world assets.BlockchainFX presale hits $6.28M with 35% bonus tokens, daily USDT rewards, and 90% APY, while Aave Horizon bridges DeFi to real-world assets.

Top Altcoins to Buy This Week: BlockchainFX Presale Surges While Aave Horizon Unlocks Institutional Liquidity

rocket bluepurple 10

How many times have you looked back at Ethereum at $0.31 or Solana at $0.22 and thought, “That could’ve been me”? Those missed ICOs turned small early entries into millionaire-making fortunes. Now, before summer ends, there’s one urgent crypto presale that screams “your second chance.” BlockchainFX ($BFX) is live, with explosive presale traction, guaranteed exchange listings, and a bonus window closing fast. Use the code AUG35 before August ends and claim 35% more tokens instantly. This is not another promise—it’s a live, revenue-generating platform offering passive income and 90% APY.

bfx 3

Claim your 35% bonus with AUG35 today—presale allocation is closing fast.

BlockchainFX ($BFX) Presale Redefines the Next 1000x Potential

BlockchainFX is already proving it isn’t just a hot crypto presale—it’s a functioning super app. Crypto, stocks, forex, and commodities trading combined into one platform, fully CertiK-audited, and KYC compliant. Over 10,000 daily users trust it already. The BFX token redistributes up to 70% of trading fees in USDT daily, with holders earning 4–7% returns per day and up to 90% APY.

The presale price has climbed from $0.02 to $0.021, with a confirmed $0.05 launch price—a guaranteed 2.3x gain before public listing. More than $6.28M has been raised by 6,786+ early adopters, alongside a $500,000 giveaway celebrating launch. Long-term forecasts put BFX above $1, with projections of $1.8B revenue by 2030 and over $630M in token rewards distributed.

Early backers are also competing in a $100,000 buy-in contest, with the top contributor already winning $50K and a Legend NFT. Add in Visa card integration (Gold, Green, Metal tiers) and Founder’s Club bonuses of up to 30% extra tokens, and the scarcity effect is undeniable. This is the presale allocation live that analysts call one of the best tokens to invest now.

bfx 1

👉 Don’t hesitate—secure $BFX today before the presale bonus closes.

Aave’s Horizon Bridges Real-World Assets—But BFX Offers Your Better Entry

DeFi leader Aave (AAVE) has just launched Horizon, a groundbreaking platform bridging DeFi with traditional finance. By enabling tokenized real-world assets like U.S. Treasuries and CLOs to serve as collateral, Aave is opening a path for institutional adoption. Backed by Chainlink’s SmartData and NAVLink, Horizon brings real-time collateral valuation, with $50M TVL on its first day. Partners include Circle, VanEck, WisdomTree, and Centrifuge—all chasing the $26B tokenized RWA market.

At today’s price of $308.30, Aave commands a market cap of $4.69B. Impressive growth, but for those who missed its early ICO, that chance is long gone. BlockchainFX offers that same “before it breaks out” entry point, with the urgency of a presale bonus closing soon.

👉 Your second chance is alive with BFX—join token presale early.

bfx 2

Comparison Table: BlockchainFX vs. Aave

ProjectLaunch YearICO/Presale PricePredicted Price End-2025Long-Term PriceSuccess Story
BlockchainFX2025$0.021 → $0.05$0.10–$0.25≥ $1Live app, 10K+ users, Visa cards, daily USDT rewards
Aave2020~$1.70 (ICO)$400+ (ATH past)Institutional DeFi leader$4.69B market cap, Horizon TVL $50M Day 1

👉 Skip regret—lock your BFX allocation today before the bonus window ends.

Conclusion: The Last Chance Before Regret Hits Again

History has shown what happens when you overlook presales that later exploded—Ethereum, Solana, even Aave. BlockchainFX is now giving early adopters one final entry. With a live super app, audited transparency, 90% APY potential, $500K giveaway, Visa card utilities, and a presale discount available now, it’s positioned as the next 100x crypto presale.

The clock is ticking. Use AUG35 before August ends for 35% more tokens, or miss out on the explosive presale opportunity everyone will talk about in 2025.

👉 Act now. Use code BLOCK30 for 30% extra tokens today.

Find Out More Information Here

Website: https://blockchainfx.com/ 

X: https://x.com/BlockchainFXcom

Telegram Chat:https://t.me/blockchainfx_chat

Market Opportunity
RealLink Logo
RealLink Price(REAL)
$0.07894
$0.07894$0.07894
-1.99%
USD
RealLink (REAL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23